Fexofenadine
- Generic Name
- Fexofenadine
- Brand Names
- Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39NO4
- CAS Number
- 83799-24-0
- Unique Ingredient Identifier
- E6582LOH6V
- Background
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of terfenadine and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
- Indication
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
- Associated Therapies
- Antihistamine
Fexofenadine in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 80
- Registration Number
- NCT05264025
- Locations
- 🇪🇬
Beni-Suef Hospital, Banī Suwayf, Egypt
🇪🇬Faculty of Medicine - Beni Suef Hospital, Banī Suwayf, Egypt
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- Conditions
- Pruritus
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 208
- Registration Number
- NCT05263206
- Locations
- 🇺🇸
FoxHall Dermatology- Site Number : 8400042, Washington, District of Columbia, United States
🇺🇸Optima Research - Boardman- Site Number : 8400039, Boardman, Ohio, United States
🇯🇵Investigational Site Number : 3920004, Habikino, Japan
Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm
- Conditions
- Ureter StoneRenal Colic
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT05150899
Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment
- Conditions
- ColdFlu Symptom
- Interventions
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 478
- Registration Number
- NCT05118672
- Locations
- 🇧🇷
Clinica de Alergia Martti Antila, Sorocaba, SP, Brazil
🇧🇷Eurofarma Laboratórios S.A, São Paulo, Brazil
Effect of Antihistamines on Ureteral Stent-Related Symptoms
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 78
- Registration Number
- NCT04726345
- Locations
- 🇺🇸
Columbia University Irving Medical Center/NYP, New York, New York, United States
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 600
- Registration Number
- NCT04688788
- Locations
- 🇩🇰
Department of Neurology, Herlev Hospital, Herlev, Denmark
🇩🇰Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
Excipient Effect on Drug Absorption in Humans
- Conditions
- The Impact of Excipients on Drug Absorption
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 12
- Registration Number
- NCT04534153
- Locations
- 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States
Histamine H1/H2 Receptors and Training Adaptations
- Conditions
- Exercise TrainingPhysical Activity
- Interventions
- Other: LactoseOther: High-intensity interval training (HIIT)
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University Ghent
- Target Recruit Count
- 19
- Registration Number
- NCT04450134
- Locations
- 🇧🇪
Department of Movement and Sports Sciences, Ghent University, Gent, Oost-Vlaanderen, Belgium
Role of Fexofenadine in Diabetic Kidney Disease
- Conditions
- Diabetic Kidney Disease
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04224428
- Locations
- 🇪🇬
Faculty of Pharmacy, Tanta University, Tanta, Egypt
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
- Conditions
- Gout
- Interventions
- Biological: PegloticaseDietary Supplement: folic acidDrug: placeboDrug: gout flare prophylaxis regimen
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT03994731
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC-East, Mesa, Arizona, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸Prohealth Research Center, Doral, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.